rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    DSGN
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Design Therapeutics (DSGN) Receives a Buy from Leerink Partners

      Detailed price information for Design Therapeutics Inc (DSGN-Q) from The Globe and Mail including charting and trades.

      Oct 14The Globe and MailDSGN
      Design Therapeutics: DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027

      Design Therapeutics initiated at Hold: DT-216P2 shows early FA RESTORE-FA gains; watch Q4 '26/Q1 '27 catalysts and cash runway. Click for more on DSGN stock.

      Oct 4Seeking AlphaDSGN
      Design Therapeutics a new overweight at Wells Fargo on Friedreich ataxia program

      Wells Fargo rates Design Therapeutics overweight, citing DT-216P2’s RESTORE-FA data and best-in-disease potential vs Skyclarys. Read more here.

      Oct 2Seeking AlphaDSGNWFC
      Wells Fargo Initiates Design Therapeutics at Overweight With $26 Price Target
      Oct 2Yahoo FinanceDSGN
      Design Therapeutics at Cantor conference: biomarker push takes center stage
      Sep 9Investing.comDSGN
      Wall Street Moves on MAA, Rivian and Design Therapeutics: One Upgrade, One Target Trim and a Biotech on Watch

      An EV maker on the rebound, a Sun Belt landlord facing fresh headwinds, and a clinical-stage biotech sitting on pivotal pipeline data have all landed on analysts' radars this week for very different reasons.

      Aug 27Yahoo FinanceDSGN

      This is the newest page. Registered accounts read further back.